FRONTEO Opens Its Own AI Drug Discovery Base 'KIBIT AI Biology Lab'

FRONTEO Inc. has announced the opening of 'KIBIT AI Biology Lab', its proprietary AI drug discovery base. This facility will serve as the core for the company's AI drug discovery business and joint research with academia. Staffed by dozens of researchers and AI engineers, the lab will focus on target molecule discovery and hypothesis generation. The initiative aims to accelerate the expansion of its licensing pipeline to pharmaceutical companies, particularly in rare diseases and cancer fields. Furthermore, the AI drug discovery support service 'DDAIF' will be significantly updated to incorporate wet lab and clinical research data, drastically improving analysis accuracy.